Ubs Group Ag Graybug Vision, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.46 - $1.05 $2,376 - $5,425	5,167 Added 2472.25%	5,376 $2,000
Q3 2022 Nov 10, 2022	SELL	$0.93 - $1.18 $14,680 - $18,626	-15,785 Reduced 98.69%	209 $0
Q2 2022 Aug 10, 2022	BUY	$0.76 - $1.25 $6,491 - $10,677	8,542 Added 114.63%	15,994 $17,000
Q1 2022 May 16, 2022	BUY	$1.13 - $1.93 $5,035 - $8,600	4,456 Added 148.73%	7,452 $9,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $3.6 $4,849 - $10,033	2,787 Added 1333.49%	2,996 $5,000
Q2 2021 Aug 13, 2021	SELL	$3.53 - $6.1 $6,530 - $11,285	-1,850 Reduced 89.85%	209 $1,000
Q1 2021 May 12, 2021	BUY	$5.55 - $35.0 $4,223 - $26,635	761 Added 58.63%	2,059 $11,000
Q4 2020 Feb 11, 2021	BUY	$13.05 - $33.93 $12,697 - $33,013	973 Added 299.38%	1,298 $38,000
Q3 2020 Nov 12, 2020	BUY	$12.71 - $16.5 $4,130 - $5,362	325 New	325 $4,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.